Compounded GLP-1 Telehealth Comparison Highlights Pricing, Clinician Review and FDA Approval Gaps
核心洞察
Two source comparisons detail compounded GLP-1 telehealth offerings from Omzo (搜索), LTTL (搜索) and BreezeMeds (搜索), with listed starting prices ranging from $179 to $399 per month.
All three platforms state compounded semaglutide and tirzepatide products are not FDA approved and have not been reviewed by the agency for safety, effectiveness or quality.
Omzo (搜索) lists compounded semaglutide from $179 and tirzepatide from $279, while providers may write prescriptions for branded FDA-approved medicines that Omzo does not sell or dispense.
Direct-to-consumer telehealth platforms offering compounded GLP-1 medications are competing on clinician oversight, listed starting prices and pharmacy verification claims, according to two source comparisons of Omzo (搜索) against LTTL (搜索) and BreezeMeds (搜索). Across all three platforms, the source materials state that compounded semaglutide and tirzepatide products are not FDA approved and have not been reviewed by the FDA for safety, effectiveness or quality — a regulatory qualifier each provider repeats alongside its marketing claims.
Pricing and Listed Starting Costs
Omzo (搜索) lists compounded semaglutide starting at $179 and compounded tirzepatide starting at $279, with pricing framed as included in program fees collected by Omzo. The source notes costs and terms may change.
LTTL (搜索) advertises up to $140 off the first month with a code auto applied, and the source includes repeated pricing examples such as $249 and $129 for dose packs. LTTL claims the same price at every dose.
BreezeMeds (搜索) lists semaglutide injection from $199 per month, tirzepatide injection from $299, and oral options displayed from $399; a separate $169 figure appears in the source without a clear product association. Both comparisons advise confirming total cost, eligibility, renewal terms and state availability before enrolling.
Clinician Review and Prescription Pathways
Omzo (搜索) connects users with licensed U.S. providers who review plans and determine eligibility, with providers making the final determination on whether to prescribe any medication. The source states clinical services are provided by third-party networks of U.S.-licensed clinicians and that using the website does not create a doctor-patient relationship. Omzo also states providers may write prescriptions for branded FDA-approved medicines, but Omzo does not sell, dispense or ship branded drugs.
LTTL (搜索) states treatment is available only when a licensed clinician determines it is medically appropriate; the captured source material does not include branded prescription pathway language. BreezeMeds (搜索) likewise indicates treatment is available only when a licensed clinician determines it is medically appropriate, referring to an online intake and personalized treatment plan.
Compounding Status and Pharmacy Practices
Omzo (搜索) states its compounded drugs are prepared and shipped by a state-licensed sterile compounding pharmacy and are produced in FDA-registered facilities, while remaining not FDA approved. LTTL (搜索) states its compounded GLP-1 medications are compounded by U.S.A. licensed pharmacies, independently verified in FDA-registered labs, and delivered to the patient's door.
BreezeMeds (搜索) states that when compounded medications are offered they are not FDA approved and are not reviewed by the FDA for safety, effectiveness or quality, and notes that medication-specific approval status must be confirmed and that branded and compounded products are not interchangeable.
Dose Verification, Delivery and Guarantees
LTTL (搜索) includes quality-control claims that doses are confirmed every three to six months to stay within plus or minus 10 percent of target strength. Omzo (搜索) emphasizes fast, discreet delivery and FSA and HSA eligibility, and states that medication costs are included in fees collected by Omzo, which pays the pharmacies; rates may vary based on pharmacy capacity, state regulations and order details.
BreezeMeds (搜索) emphasizes discreet home delivery and ongoing support, and asks users to confirm which states it services along with insurance acceptance and fees.
On outcomes messaging, the Omzo (搜索) source includes a patient example quote alongside multiple statements stressing no guarantees, noting individual results may vary and weight loss is not guaranteed. LTTL (搜索)'s material includes claims about helping regulate appetite and promote fullness to support weight loss, while repeating that treatment is available only when a licensed clinician determines it is medically appropriate.
What the Comparisons Advise
Both source comparisons frame the choice around patient priorities rather than demonstrated clinical superiority: Omzo (搜索) for an explicit clinician-guided compounded program with lower listed starting prices and a branded prescription pathway, LTTL (搜索) for an initial promotional discount and stated dose-verification practices, and BreezeMeds (搜索) for injectable and oral GLP-1 options with discreet home delivery. All sources advise confirming eligibility, medication details, total cost, renewal terms and state availability before enrollment, and all state that compounded medications are not FDA approved.